Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rxo (RXO) Operating Expenses (2021 - 2025)

Rxo (RXO) has disclosed Operating Expenses for 5 consecutive years, with $200.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 8.26% year-over-year to $200.0 million, compared with a TTM value of $832.0 million through Dec 2025, up 24.92%, and an annual FY2025 reading of $832.0 million, up 24.92% over the prior year.
  • Operating Expenses was $200.0 million for Q4 2025 at Rxo, down from $208.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $218.0 million in Q4 2024 and bottomed at $144.0 million in Q2 2023.
  • Average Operating Expenses over 5 years is $169.5 million, with a median of $155.0 million recorded in 2022.
  • The sharpest move saw Operating Expenses dropped 13.25% in 2023, then surged 49.32% in 2024.
  • Year by year, Operating Expenses stood at $152.0 million in 2021, then grew by 1.97% to $155.0 million in 2022, then decreased by 5.81% to $146.0 million in 2023, then soared by 49.32% to $218.0 million in 2024, then fell by 8.26% to $200.0 million in 2025.
  • Business Quant data shows Operating Expenses for RXO at $200.0 million in Q4 2025, $208.0 million in Q3 2025, and $214.0 million in Q2 2025.